Marketing Pharmaceutical research Prescription 
World of DTC Marketing
NOVEMBER 3, 2021
High drug prices preferentially benefit the largest drug manufacturers, which spend only about 10 to 20 percent of their revenue on research and development — far less than they spend on marketing, administration, and stock buybacks and dividends. 12 of the 16 most profitable companies in Q2 were pharmaceutical firms.
Pharmaceutical Technology
JULY 23, 2008
The world’s biggest pharmaceutical company Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. Why aren’t we seeing more cancer treatments on the market? There’s been a huge change in the market.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
MAY 3, 2023
Pharmaceutical research and development: what do we get for all that money? Industry-sponsored clinical research: a broken system. Powerful medicines: the benefits, risks, and costs of prescription drugs. The post The Dark Side of the Pharmaceutical Industry: Are Treatments Being Blocked for Profit? Fugh-Berman, A.
World of DTC Marketing
APRIL 14, 2021
Best of all are patients in the US, where prices are highest, and with chronic conditions requiring repeat prescriptions. The argument is that this is the only way to cover research and development (R&D) cost for new drugs. The best prospects are drugs targeted at patients who are high-value and who will use the drugs long term.
World of DTC Marketing
AUGUST 16, 2021
SUMMARY: President Biden wants to lower prescription drug costs. Even though prescription drug costs are only $.11 The Pharmaceutical Research and Manufacturers of America raised nearly $527 million last year and spent roughly $506 million, new tax returns obtained by OpenSecrets reveal.
pharmaphorum
AUGUST 5, 2022
In addition to the climate provisions, however, the bill has a significant effect on prescription drug prices, and according to reports neither Manchin nor Sinema is objecting to these provisions, which are similar but not identical to the ones in the Build Back Better plan which previously passed in the House of Representatives.
World of DTC Marketing
JANUARY 27, 2022
According to the federal Centers for Medicaid and Medicare Services, our federal government spent $298 billion on prescription drugs at that time. March-in rights under Bayh-Dole have never been invoked, no doubt because the Pharmaceutical Research and Manufacturers of America, or PhRMA, has made clear that it would litigate.
Expert insights. Personalized for you.
173 
Let's personalize your content